Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
Merck's Continuous Process Improvement - Life Science Leader
WEBJul 1, 2014 · Merck embraced a process of continuous improvement after years of implementing Lean initiatives that yielded periodic improvements. With Lean, Six Sigma, Kaizen, Agile, total quality management, and other process improvement approaches, after an initial surge, results sometimes slipped backwards to baseline levels.
Gaurav Shah — A Rare Disease Biopharma CEO Shares A Rare …
WEBFeb 6, 2020 · Gaurav Shah, M.D., is the CEO of Rocket Pharmaceuticals, a publicly traded (NASDAQ: RCKT) biopharmaceutical company. “We’re a relatively new company, about four years old, with four programs already in the clinic and another on the way,” he says. Being a platform agnostic gene therapy company, Rocket’s …
How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell …
WEBAug 1, 2019 · Advice From A Successful Serial Entrepreneur. Robert Hariri, M.D., Ph.D., a successful serial entrepreneur and CEO of Celularity, believes a lot of companies fail because they have a very linear development strategy. And if they reach a milestone and fail, there isn’t much of a future. “A lot of scientists have a discovery — a molecule, a ...
Life Science Connect Podcast
WEBOn today’s episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials. 001: The JPM Conference. In this episode, Life Science Leader magazine ...
Building A 1 Billion Gene Therapy Company — In 6 Years
WEBOct 1, 2019 · Building A $1 Billion Gene Therapy Company — In 6 Years. “THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall of 2012, and Patterson was preparing a final pitch to OrbiMed Advisors to lead a ...
FDA INTERACT Meetings: Early Interactions For Cell And Gene …
WEBFDA INTERACT Meetings: Early Interactions For Cell And Gene Therapy Sponsors. By Annette F. Arlinghaus, Director, Regulatory Operations and Stacey A. Ayres, PhD Vice President, Regulatory Strategy. Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well ...
The Top CROs By Therapeutic Indication Share Strong Regulatory …
WEBAug 30, 2013 · The leading CROs for oncology projects based on customer perception were Eurofins and Covance, each with a CP of 77 percent, followed by Charles River Labs and INC Research, both at 75 percent, and Harlan Labs (74 percent). Covance and Eurofins received their strongest scores in productivity and regulatory compliance.
How To Overcome The Challenge Of Valuing A Biotech
WEBDec 30, 2019 · Companies generally use one of three common valuation frameworks to value their company: the net asset value (NAV) method, a form of the cost approach; the discounted cash flow (DCF) method, a form of the income approach; or a market approach. Biotech is better off using the NAV or DCF methods because finding comparables for the market approach ...
Articles by Ben Comer - Life Science Leader
WEBJun 14, 2024 · Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where …
Skip to content